Suppr超能文献

儿童淋巴细胞白血病的细胞遗传学与预后:英国医学研究委员会UKALL X研究结果。英国医学研究委员会儿童白血病工作组

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.

作者信息

Chessels J M, Swansbury G J, Reeves B, Bailey C C, Richards S M

机构信息

Haematology/Oncology Department, Institute of Child Health, London.

出版信息

Br J Haematol. 1997 Oct;99(1):93-100. doi: 10.1046/j.1365-2141.1997.3493163.x.

Abstract

We have analysed the prognostic influence of cytogenetic findings at diagnosis in a group of 502 children with acute lymphoblastic leukaemia (ALL), treated on MRC UKALL X, in whom clonal cytogenetic abnormalities were detected at diagnosis. Despite the overall improvement in outcome in children treated on this protocol compared with previous trials, some cytogenetically-defined groups were still associated with a poor outcome and ploidy retained some prognostic significance. Patients with high hyperdiploid ALL (39% of those with clonal abnormalities) had a favourable outcome with event free survival of 71% at 5 years. Those with near haploidy (1%), hypodiploidy (9%) and low hyperdiploidy (16.5%) had a relatively poor prognosis with event-free survival at 5 years of 17%, 42% and 49% respectively. Only two of 12 children with Ph-positive leukaemia are alive in remission and abnormalities of chromosome 11q23 were also associated with a high risk of treatment failure. In contrast, the t(1;19) was associated with improved event-free survival of 87.5% at 5 years. A number of other non-random abnormalities were identified with no clear prognostic significance. We conclude that identification of certain genetic changes remains important in the management of acute lymphoblastic leukaemia, although whether molecular diagnosis of clinically relevant abnormalities can now supplant cytogenetics in the clinical trials context remains to be determined.

摘要

我们分析了502例急性淋巴细胞白血病(ALL)患儿诊断时细胞遗传学结果的预后影响,这些患儿接受了英国医学研究理事会(MRC)UKALL X方案治疗,且诊断时检测到克隆性细胞遗传学异常。尽管与先前试验相比,接受该方案治疗的患儿总体预后有所改善,但一些细胞遗传学定义的组仍与不良预后相关,并且倍性仍具有一定的预后意义。高二倍体ALL患者(占克隆性异常患者的39%)预后良好,5年无事件生存率为71%。近单倍体(1%)、亚二倍体(9%)和低二倍体(16.5%)患者的预后相对较差,5年无事件生存率分别为17%、42%和49%。12例Ph阳性白血病患儿中只有2例存活且处于缓解期,11q23染色体异常也与高治疗失败风险相关。相比之下,t(1;19)与5年87.5%的无事件生存率提高相关。还发现了一些其他非随机异常,但无明确的预后意义。我们得出结论,确定某些基因变化在急性淋巴细胞白血病的管理中仍然很重要,尽管在临床试验背景下,临床相关异常的分子诊断现在是否可以取代细胞遗传学仍有待确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验